Tocilizumab for the treatment of COVID-19

Flisiak, Robert; Flisiak-Jackiewicz, Marta; Rzymski, Piotr; Zarębska-Michaluk, Dorota

doi:10.1080/14787210.2023.2226867

Cited by 2 publications

(1 citation statement)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The emergence of SARS-CoV-2 has also led to an unprecedented scientific response encompassing essential research on diagnostic methods and studies of COVID-19 immunology, viral pathogenicity, and potential therapeutic targets [ 17 , 18 ]. Various pharmaceuticals (e.g., arbidol hydroxychloroquine, darunavir, lopinavir, favipiravir, remdesivir, ribavirin, ritonavir, interferons, dexamethasone, and tocilizumab) have been repurposed for COVID-19 treatment, with mixed effectiveness results [ 19 , 20 , 21 , 22 ]. The use of convalescent plasma was eventually abandoned due to the lack of clinical benefits observed in severely ill patients [ 23 , 24 ], while the effectiveness of different monoclonal antibodies has been dramatically impacted by SARS-CoV-2’s evolution [ 25 , 26 ].…”

Section: Introductionmentioning

confidence: 99%

Key Considerations during the Transition from the Acute Phase of the COVID-19 Pandemic: A Narrative Review

Rzymski,

Pokorska-Śpiewak,

Jackowska

et al. 2023

Vaccines

Self Cite

View full text Add to dashboard Cite

The COVID-19 pandemic has been met with an unprecedented response from the scientific community, leading to the development, investigation, and authorization of vaccines and antivirals, ultimately reducing the impact of SARS-CoV-2 on global public health. However, SARS-CoV-2 is far from being eradicated, continues to evolve, and causes substantial health and economic burdens. In this narrative review, we posit essential points on SARS-CoV-2 and its responsible management during the transition from the acute phase of the COVID-19 pandemic. As discussed, despite Omicron (sub)variant(s) causing clinically milder infections, SARS-CoV-2 is far from being a negligible pathogen. It requires continued genomic surveillance, particularly if one considers that its future (sub)lineages do not necessarily have to be milder. Antivirals and vaccines remain the essential elements in COVID-19 management. However, the former could benefit from further development and improvements in dosing, while the seasonal administration of the latter requires simplification to increase interest and tackle vaccine hesitancy. It is also essential to ensure the accessibility of COVID-19 pharmaceuticals and vaccines in low-income countries and improve the understanding of their use in the context of the long-term goals of SARS-CoV-2 management. Regardless of location, the primary role of COVID-19 awareness and education must be played by healthcare workers, who directly communicate with patients and serve as role models for healthy behaviors.

show abstract